Role of Apolipoprotein E Genotypes in Aneurysmal Subarachnoid Hemorrhage: Susceptibility, Complications, and Prognosis.
Role of Apolipoprotein E Genotypes in Aneurysmal Subarachnoid Hemorrhage: Susceptibility, Complications, and Prognosis.
复制标题
载脂蛋白 E 基因型在动脉瘤性蛛网膜下腔出血中的作用：易感性、并发症和预后。
DOI：
10.1016/j.wneu.2018.07.019
复制
发表时间：
2018
影响因子：
2
通讯作者：
Yan Jiang
中科院分区：
文献类型：
--
作者：
Xin Hu;Zhiyi Xie;Xin Zan;Lu Ma;Hao Li;C. You;Yan Jiang
背景动脉瘤性蛛网膜下腔出血（aSAH）是一种毁灭性的疾病。新的证据表明，载脂蛋白E（ApoE）基因型可能与aSAH的风险以及aSAH后的并发症和结局相关，尽管结果仍存在争议。方法我们检索了PubMed、Embase、中国国家知识基础设施和万方数据库中已发表的文献，以识别涉及ApoE基因型和aSAH的研究。通过荟萃分析总结 Apo 基因型与 aSAH 之间的关系，包括易感性、并发症和预后。结果 18 项研究被认为符合纳入条件。一般来说，ε4 携带者发生 aSAH 的风险增加（比值比 [OR] 1.23，95% 置信区间 [CI] 1.01–1.49）。具有ε2/ε2基因型的白人患者患aSAH的风险更大（OR 3.38，95% CI 1.13–10.11）。与非ε4携带者相比，携带ε4等位基因的aSAH患者预后不良的风险增加（OR 2.21，95% CI 1.21–4.05），特别是在亚洲患者中（OR 4.99，95% CI 1.73–14.40）。与总体人群中的非ε4携带者相比，ApoE ε4携带者迟发性缺血性神经功能缺损的风险增加。某些Apo基因型对aSAH入院严重程度、再出血或aSAH后脑血管痉挛的影响没有检测到显着差异。结论我们发现Apo基因型与aSAH风险显着相关，但其对某些种族人群的影响不同。携带ε4等位基因的患者可能有更差的结果，而目前的证据不足以证明Apo基因型与SAH后并发症之间的关联。
BackgroundAneurysmal subarachnoid hemorrhage (aSAH) is a devastating disease. Emerging evidence has indicated that the apolipoprotein E (ApoE) genotype might be associated with the risk of aSAH as well as complications and outcomes after aSAH, although the results remain controversial.MethodsWe searched published literature on PubMed, Embase, China National Knowledge Infrastructure, and Wanfang database to identify studies involving theApoEgenotype and aSAH. A meta-analysis was performed to summarize the relationship betweenApoEgenotype and aSAH, including susceptibility, complications, and prognosis.ResultsEighteen studies were considered eligible for inclusion. Generally,ε4carriers had increased risk of aSAH (odds ratio [OR] 1.23, 95% confidence interval [CI] 1.01–1.49). White patients with theε2/ε2genotype had a greater risk of aSAH (OR 3.38, 95% CI 1.13–10.11). The patients with aSAH carrying theε4allele had an increased risk of poor outcome (OR 2.21, 95% CI 1.21–4.05) compared with non-ε4carriers, especially in Asian patients (OR 4.99, 95% CI 1.73–14.40).ApoE ε4carriers have increased risk of delayed ischemic neurologic deficit compared with non-ε4carriers in the overall population. No significant difference was detected regarding the effect of certainApoEgenotypes on aSAH admission severity, rebleeding, or cerebral vasospasm after aSAH.ConclusionsWe found that theApoEgenotype was significantly associated with aSAH risk, whereas its effect on certain ethnic populations differs. Patient carrying theε4allele might have a worse outcome, whereas current evidence was insufficient to prove the association betweenApoEgenotypes and post-SAH complications.
影响因子：
7.7
作者：
Khan, Tauseef A.;Shah, Tina;Casas, Juan P.
通讯作者：
Casas, Juan P.